Skip to content

Avalo 制药

US · AVTX #3484 按市值排名
11.27 -0.74 -6.16%
实时 - 追踪5344个代码 - 心跳于2秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量增加了2家。
  • 机构持股总比例下降了0.7个百分点。

机构持股

机构持股比例
136.44% -0.71pp
机构数量
152 +2
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Hedge Fund64.86%
Mutual Fund45.73%
VC/PE Fund18.62%
Public Company5.76%
Individual/Insider1.54%
Sovereign Wealth Fund0.84%
Private Company0.42%
Insurance Company0.17%

主要股东 截至 2026-07-31

FMR 10.70% · 5.74M 股
BlackRock 8.14% · 4.37M 股
Deep Track Capital, LP 6.73% · 3.61M 股
Caligan Partners, LP 5.90% · 3.16M 股
TCG Crossover Management, LLC 5.63% · 3.02M 股
Affinity Asset Advisors, LLC 5.41% · 2.90M 股
State Street Global Advisors 5.39% · 2.89M 股
Vanguard Capital Management, LLC 4.83% · 2.59M 股
Farallon Capital Management, L.L.C. 4.66% · 2.50M 股
Point72 Asset Management, L.P. 4.45% · 2.39M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 20次买入 · 30次卖出

姓名职务持股比例
Patrick Crutcher Former Chief Strategy Officer 1.02%
Garry Neil Chairperson & CEO 0.35%
Christopher Sullivan CFO & Head of Investor relations 0.07%
Paul Varki Chief Legal Officer 0.02%
Mittie Doyle Chief Medical Officer 0.02%
Aaron Kantoff Independent Director 0.01%
Samantha Truex Independent Director 0.01%
Gilla Kaplan Independent Director 0.01%
June Almenoff Independent Director 0.01%
Jonathan Goldman Independent Director 0.01%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-29 Kevin Lind Director Other Derivative Acquisition +1,352 $15.33
2026-09-29 Rita Jain Director Other Derivative Acquisition +1,322 $15.33
2026-09-29 Ron Philip Independent Director Other Derivative Acquisition +1,109 $15.33
2026-09-15 Christopher Sullivan CFO & Head of Investor relations Derivative Exercise and Sale -12,394 $9.88–16.33
2026-09-09 Christopher Sullivan CFO & Head of Investor relations Derivative Exercise and Sale -10,185 $8.04–17.62
2026-08-27 Mittie Doyle Chief Medical Officer Derivative Exercise and Sale -679 $8.04–20.00
2026-08-17 Christopher Sullivan CFO & Head of Investor relations Derivative Exercise and Sale -71,852 $9.88–20.05
2026-08-16 Mittie Doyle Chief Medical Officer Derivative Exercise and Sale -1,000 $12.65–20.00
2026-08-16 Christopher Sullivan CFO & Head of Investor relations Open Market Disposition -873 $19.94
2026-08-10 Jennifer Riley Chief Strategy Officer Open Market Disposition -2,655 $19.59
2026-08-09 Mittie Doyle Chief Medical Officer Derivative Exercise and Sale -679 $8.04–20.00
2026-07-26 Mittie Doyle Chief Medical Officer Derivative Exercise and Sale -1,000 $12.65–20.00
2026-06-29 Kevin Lind Director Other Derivative Acquisition +1,105 $18.48
2026-06-29 Mittie Doyle Chief Medical Officer Derivative Exercise and Sale -4,654 $8.04–20.00
2026-06-29 Rita Jain Director Other Derivative Acquisition +1,080 $18.48
2026-06-29 Ron Philip Independent Director Other Derivative Acquisition +69 $18.48
2026-06-22 Mittie Doyle Chief Medical Officer Derivative Exercise and Sale -1,450 $8.04–18.00
2026-06-22 Ron Philip Independent Director Other Derivative Acquisition +40,200 $17.83
2026-06-09 Mittie Doyle Chief Medical Officer Sale to Issuer -1,084 $13.10
2026-06-09 Paul Varki Chief Legal Officer Sale to Issuer -1,081 $13.10

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:18 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

Avalo 制药 讨论区 0 条评论

发表评论